Sun Pharmaceutical Industries Ltd (SUN.BO)

SUN.BO on Bombay Stock Exchange

854.55INR
28 Aug 2014
Price Change (% chg)

Rs-7.25 (-0.84%)
Prev Close
Rs861.80
Open
Rs858.30
Day's High
Rs863.45
Day's Low
Rs850.00
Volume
83,136
Avg. Vol
145,163
52-wk High
Rs875.00
52-wk Low
Rs493.50

SUN.BO

Chart for SUN.BO

About

Sun Pharmaceutical Industries Limited is an international specialty pharma company. The Company manufactures and markets pharmaceutical formulations as branded generics, as well as generics in India, the United states and several other markets across the world. The Company’s business is divided into four segments: US Generics,... (more)

Overall

Beta: 0.67
Market Cap (Mil.): Rs1,771,363.00
Shares Outstanding (Mil.): 2,071.16
Dividend: 1.50
Yield (%): 0.18

Financials

  SUN.BO Industry Sector
P/E (TTM): 30.12 32.64 33.56
EPS (TTM): 28.39 -- --
ROI: -- 18.00 17.31
ROE: -- 18.64 18.05
Search Stocks

Sun Pharma posts Q1 profit on strong U.S. sales

MUMBAI - Sun Pharmaceutical Industries Ltd, India's largest drugmaker by market value, reported a better-than-expected first-quarter profit, reflecting higher sales in its largest market, the United States.

13 Aug 2014

Sun Pharma gains after earnings beat estimates

Reuters Market Eye - Sun Pharmaceutical Industries gains 1.6 percent after June-quarter earnings beat estimates on higher U.S. sales.

13 Aug 2014

MARKET EYE -India's Sun Pharma gains after earnings beat estimates

* Sun Pharmaceutical Industries gains 1.6 percent after June-quarter earnings beat estimates on higher U.S. sales. * Sequential rise of 20 percent in U.S. sales is a positive surprise, analysts say. (abhishek.vishnoi@thomsonreuters.com / abhishek.vishnoi.thomsonreuters.com@reuters.net)

13 Aug 2014

Ranbaxy posts loss on provision for U.S. settlement

MUMBAI - Generic drugmaker Ranbaxy Laboratories Ltd posted a net loss for the quarter to end-June after making a provision related to "ongoing settlement discussions" with U.S. government authorities.

29 Jul 2014

India's Ranbaxy Laboratories posts loss in June quarter

MUMBAI, July 29 - Indian drugmaker Ranbaxy Laboratories Ltd, which has agreed to be acquired by local rival Sun Pharmaceutical Industries Ltd, posted a net loss in the June quarter hit by a one-time provision.

29 Jul 2014

Sun Pharma acquires U.S.-based Pharmalucence

MUMBAI - Sun Pharmaceutical Industries Ltd , India's third-largest generic drugmaker by sales, said on Wednesday it had acquired U.S.-based Pharmalucence Inc, which has sterile injectable capacity and research capabilities.

16 Jul 2014

India's Sun Pharma acquires U.S.-based Pharmalucence

MUMBAI, July 16 - Sun Pharmaceutical Industries Ltd, India's third-largest generic drugmaker by sales, said on Wednesday it had acquired U.S.-based Pharmalucence Inc, which has sterile injectable capacity and research capabilities.

16 Jul 2014

BSE Sensex edges higher; defensive stocks surge

MUMBAI - The BSE Sensex and Nifty rose on Friday as defensive stocks such as Sun Pharmaceutical Industries and Ranbaxy Laboratories jumped on the U.S. regulator's approval for a key drug while IT stocks gained after rival Accenture Plc reported robust quarterly revenue growth.

27 Jun 2014

Indian shares edge higher; defensives surge

* BSE index gains 0.15 pct; NSE ends 0.21 pct higher * Century Textile rallies after investor Damani buys stake * Aban likely to launch up to $150 mln share sale on Friday - sources * Ranbaxy gets FDA approval for Novartis's Diovan generic By Abhishek Vishnoi MUMBAI, June 27 - Indian shares rose on Friday as defensive stocks such as Sun Pharmaceutical Industries and Ranbaxy Laboratories jumped on the U.S. regulator's approval for a key drug while IT stocks gained

27 Jun 2014

Indian shares edge higher; defensive stocks surge

MUMBAI, June 27 - Indian shares rose on Friday as defensive stocks such as Sun Pharmaceutical Industries and Ranbaxy Laboratories jumped on the U.S. regulator's approval for a key drug while IT stocks gained after rival Accenture Plc reported robust quarterly revenue growth.

27 Jun 2014

Earnings vs. Estimates

Search Stocks